4-bromo-3,5-dimethoxyphenylisopropylamine | 32156-34-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-3,5-dimethoxyphenylisopropylamine
• 英文别名: 3,5-dimethoxy-4-bromoamphetamine；(+/-)-4-Brom-3,5-dimethoxy-amphetamin；4-Bromo-3,5-dimethoxy-amphetamin；4-Bromo-3,5-dimethoxyamphetamine；1-(4-bromo-3,5-dimethoxyphenyl)propan-2-amine
• CAS: 32156-34-6
• 化学式: C₁₁H₁₆BrNO₂
• 分子量: 274.158
• InChiKey: FAVLJTSHWBEOMA-UHFFFAOYSA-N

物化性质

• 沸点：
  351.5±37.0 °C(Predicted)
• 密度：
  1.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-溴-3,5-二甲氧基苯甲醛 在 lithium aluminium tetrahydride 、 ammonium acetate 作用下， 以 溶剂黄146 为溶剂， 生成 4-bromo-3,5-dimethoxyphenylisopropylamine
  参考文献：
  名称：

  潜在的拟精神病药物。溴甲氧基苯丙胺。

  摘要：

  DOI：

  10.1021/jm00286a026

文献信息

• [EN] PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS<br/>[FR] PHÉNALKYLAMINES ET PROCÉDÉS DE TRAITEMENT DE TROUBLES DE L'HUMEUR
  申请人：GILGAMESH PHARMACEUTICALS INC

  公开号：WO2022006186A1

  公开（公告）日：2022-01-06

  Phenalkylamines and methods of treating mood disorders with phenalkylamines. Also provided are pharmaceutical compositions that include phenalkylamines.

  Phenalkylamines和使用Phenalkylamines治疗情绪障碍的方法。还提供了包含Phenalkylamines的制药组合物。
• Halogen treatment of heart attack and ischemic injury
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10201570B2

  公开（公告）日：2019-02-12

  The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

  本发明涉及卤素化合物（包括碘化物）和卤代化合物（包括碘化物、硫化物和硒）在治疗和预防疾病和伤害方面的用途。本发明进一步涉及包含卤素化合物和/或卤化金属化合物的组合物，包括药物组合物，以及制造此类化合物和向需要的受试者施用此类组合物的方法。
• 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT_2A Partial Agonists
  作者：Cynthia S. Dowd、Katharine Herrick-Davis、Christina Egan、Ann DuPre、Carol Smith、Milt Teitler、Richard A. Glennon

  DOI：10.1021/jm9906062

  日期：2000.8.1

  Phenylalkylamines such as 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB; Pa) and its corresponding iodo derivative DOI (2) are commonly used 5-HT2 serotonin agonists. Previous studies have established that the 2,5-dimethoxy substitution pattern found in these compounds is optimal for high affinity at 5-HT2A receptors and that substituents at the 4-position can modulate affinity over a wide range. We have previously shown, however, that when the 4-position is substituted with a 3-phenylpropyl substituent (i.e., 3), the compound binds with an affinity comparable to that of Pa but that it possesses 5-HT2A antagonist character. The present study examined the structure-affinity relationships of 3, and the results were very much unexpected. That is, the 2,5-dimethoxy substitution pattern of 3 is not required for high affinity. Either of the two methoxy groups can be removed without untoward effect on affinity, and relocation of the methoxy substituents actually enhances affinity by as much as an order of magnitude. None of the compounds displayed more than 20-fold selectivity for 5-HT2A over 5-HT2C receptors. In addition, several were demonstrated to act as 5-HT2A partial agonists. As such, the results of this study suggest that the structure-affinity relationships of phenylalkylamines as 5-HT2A ligands now be reinvestigated in greater detail.
• HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY
  申请人：Fred Hutchinson Cancer Research Center

  公开号：EP3104939A1

  公开（公告）日：2016-12-21
• USE OF HALOGEN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE INJURY AND POST-INTENSIVE CARE SYNDROME
  申请人：Faraday Pharmaceuticals, Inc.

  公开号：EP3801565A1

  公开（公告）日：2021-04-14